MiRna in Breast Cancer

Profiling the circulating miR-639 and miR-10b in Egyptian breast cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201706002246188

Enrollment

Registered

2017-05-01

Start date

2015-03-03

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Cancer

Interventions

Serum sample

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. All women were initially identified for study participation by physicians at the NCI during (March 2015-August 2015). 2. Participants were all chosen to be female recently diagnosed breast cancer. 3. Patients of various stages not receiving any treatment for this pathologic condition and not have another types of cancer such as (ovarian, uterine, liver, lung, bone¿¿¿. etc.).

Exclusion criteria

Exclusion criteria: 1. Patients receiving a chemotherapeutic treatment. 2. Have other types of cancer such as (ovarian, uterine, liver, lung, bone¿. etc.) 3. Pregnant female subjects also excluded.

Design outcomes

Primary

Measure	Time frame
Diagnostic efficacy of miRNAs aganist CA-15.3 and p53	—

Secondary

Measure	Time frame
Diagnostic efficacy of miRNAs aganist CA-15.3 and p53	—

Countries

Egypt

Contacts

Public ContactOssama Abd El-Motaal

Professor of Biochemistry, Biochemistry Dept., Al-Azhar University.

ossamamansour1@hotmail.com00201006180329

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026